CoChat

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists

Open access
Holst, Jens Juul, Rosenkilde, Mette Marie · 2020 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Abstract

The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food intake and improves glucose regulation in patients with type 2 diabetes (T2DM), GIP seems to be devoid of these activities, although the 2 hormones as well as their receptors are highly related. In fact, numerous studies have suggested that GIP may promote obesity. However, chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-losing and glucose-lowering efficacy in obese individuals with T2DM. At the same time, antagonists of the GIP receptor have been reported to reduce weight gain/cause weight loss in experimental animals including nonhuman primates. This suggests that both agonists and antagonist of the GIP receptor should be useful, at least for weight-losing therapy. How is this possible? We here review recent experimental evidence that agonist-induced internalization of the two receptors differs markedly and that modifications of the ligand structures, as in co-agonists, profoundly influence these cellular processes and may explain that an antagonist may activate while an agonist may block receptor signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaa327

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 2

  1. Stensen, 2019, Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific effects in obese patients with type 2 diabetes, Diabetologia., 62, S270
  2. Marks, 1988, GIP: the obesity hormone., 13

Cited by

See all 208

Metadata

Authors
Holst, J. J., & Rosenkilde, M. M.
Affiliations
University of Copenhagen (DK)
Corresponding author
  • Holst, Jens Juul
  • Rosenkilde, Mette Marie
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2020-05-27
Volume
105
Issue
8
Pages
e2710-e2716
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3030023482
Cited by
207
References
60
Citations by year
2026: 32 · 2025: 36 · 2024: 39 · 2023: 28 · 2022: 40 · 2021: 26 · 2020: 4
FWCI
3.76
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucose-dependent insulinotropic polypeptide, GIP receptor, type 2 diabetes, obesity, GIP receptor antagonist, receptor internalization, ligand structure, insulin secretion, weight loss treatment, receptor signaling
MeSH terms
Appetite, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. https://app.cochat.ai/papers/10.1210/clinem/dgaa327
The paper
Holst, J. J., & Rosenkilde, M. M. (2020). GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.